Follicular Lymphoma & Epithelioid Sarcoma: Treatment Options & Tazemetostat Approval

The drug tazemetostat, marketed as Tazverik, has been voluntarily withdrawn from markets worldwide following evidence of an increased risk of secondary hematologic malignancies – cancers of the blood – in patients treated with the drug. The decision, announced by pharmaceutical company Ipsen on March 9, 2026, impacts both its approved uses for follicular lymphoma and epithelioid sarcoma. While treatment options remain for follicular lymphoma, tazemetostat represented the sole FDA-approved therapy specifically for epithelioid sarcoma, a rare soft tissue cancer.

SYMPHONY-1 Trial Findings Prompt Withdrawal

The withdrawal stems from data generated by the phase 1b/3 SYMPHONY-1 clinical trial (NCT04224493). This trial evaluated the combination of tazemetostat with standard treatments, rituximab and lenalidomide, in patients with relapsed or refractory follicular lymphoma. An independent data monitoring committee (IDMC) determined that the emergence of these secondary hematologic malignancies in patients receiving the combination therapy suggested the risks outweighed the potential benefits. Ipsen has initiated steps to halt treatment with tazemetostat for all patients currently enrolled in the SYMPHONY-1 trial, transitioning them to standard-of-care lenalidomide/rituximab therapy. The study itself will remain open to continue long-term safety assessments.

“While Here’s an extremely disappointing outcome, the safety of patients remains our priority,” stated Christelle Huguet, PhD, executive vice president and head of Research and Development at Ipsen, in a company news release. “Emerging data from this confirmatory study have highlighted a safety profile that is unfavorable compared to that previously observed in clinical evaluation.”

Understanding Follicular Lymphoma and Epithelioid Sarcoma

Follicular lymphoma is a unhurried-growing type of non-Hodgkin lymphoma, a cancer that begins in the lymphatic system. It often presents in later stages and can be challenging to treat, particularly when it recurs after initial therapy. Epithelioid sarcoma, in contrast, is a rare and aggressive soft tissue sarcoma, typically affecting young adults. It often occurs in the extremities and can be difficult to treat effectively. The lack of dedicated therapies for epithelioid sarcoma makes the withdrawal of tazemetostat particularly concerning for patients with this diagnosis.

What Do Secondary Hematologic Malignancies Mean?

Secondary hematologic malignancies are cancers that develop as a consequence of prior cancer treatment. They can include conditions like acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The development of these malignancies suggests that the initial cancer treatment – in this case, tazemetostat – may have caused genetic damage that increased the risk of these subsequent cancers. It’s essential to note that establishing a direct causal link between tazemetostat and these malignancies requires further investigation, but the IDMC’s assessment indicates a strong enough association to warrant withdrawal of the drug.

SYMPHONY-1 Trial Design and Limitations

The SYMPHONY-1 trial was designed as a randomized, controlled phase 1b/3 study. Patients with relapsed or refractory follicular lymphoma were assigned to receive either tazemetostat in combination with rituximab and lenalidomide, or rituximab and lenalidomide alone. The primary endpoint of the trial was progression-free survival (PFS), but the emergence of secondary hematologic malignancies became a significant safety concern. It’s crucial to understand that clinical trials, even large phase 3 studies like SYMPHONY-1, have limitations. The observed association between tazemetostat and secondary cancers doesn’t definitively prove causation; other factors could contribute to the risk. The study population may not be fully representative of all patients with follicular lymphoma.

Impact on Patients and Future Treatment Strategies

The withdrawal of tazemetostat leaves a gap in the treatment landscape, particularly for patients with epithelioid sarcoma. For those with follicular lymphoma, alternative treatment options remain available, including various chemotherapy regimens, immunotherapy, and other targeted therapies. However, the loss of a specifically approved agent underscores the ongoing need for research into new and more effective treatments for both follicular lymphoma and epithelioid sarcoma. Patients currently receiving tazemetostat should consult with their healthcare providers to discuss alternative treatment plans and potential risks and benefits.

Ipsen is coordinating with the Food and Drug Administration (FDA) to formally execute the withdrawal of tazemetostat from the market (Drugs.com). This process involves removing the drug’s approval and ensuring that it is no longer available for prescription.

Next Steps: Ongoing Surveillance and Research

While the SYMPHONY-1 trial is transitioning patients to standard care, it will continue to follow all participants to assess the long-term safety outcomes. This ongoing surveillance is critical for understanding the full extent of the risks associated with tazemetostat and for informing future treatment strategies. Researchers will also be analyzing the data from the trial to identify potential biomarkers or patient characteristics that may predict an increased risk of secondary hematologic malignancies. This information could facilitate to personalize treatment decisions and minimize the risk of adverse events in the future. Further research is needed to explore alternative therapeutic approaches for both follicular lymphoma and epithelioid sarcoma, with a focus on developing safer and more effective treatments.